Esmya (ulipristal acetate) / ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company - LARVOL DELTA

Management of Bleeding Irregularities during Contraceptive Implant Use: A Systematic Review. (PubMed, Contraception) - "Implications: Patients experiencing bothersome bleeding irregularities during contraceptive implant use may be offered different options to manage bleeding and improve their satisfaction. More data are needed on the effectiveness of specific interventions (drugs, regimens, and repeat dosing) and patient satisfaction outcomes."

Clinical • Journal • Review • Long-acting Reversible Contraceptives

The Use and Effectiveness of Different Emergency Contraception Methods Among Adolescent Girls and Young Women in a Greek Clinic: A Cross-Sectional, Comparative, Observational Study. (PubMed, Clin Pract) - "Emergency contraception pills contain either levonorgestrel (a single 1.5 mg dose, effective within 72 h) or ulipristal acetate (a single 30 mg dose, effective within 120 h), both of which are most effective when taken as soon as possible after unprotected intercourse...However, Christians were significantly more likely to use emergency contraception due to missed contraceptive doses (20.9% vs. 6.7%, p = 0.004) or the failure to take a progesterone-only pill (19.1% vs. 3.3%, p = 0.001)... Both religious and individual sociodemographic factors affect not only the choice of emergency contraception but also the urgency with which the emergency contraception is used. Interventions aimed at improving contraception education, addressing partner-related challenges, and promoting timely access could improve reproductive health outcomes."

Journal • Observational data • Long-acting Reversible Contraceptives

Exploring Postpartum Use of Advance Provision of Ulipristal Acetate and Its Promotion of Reproductive Autonomy. (PubMed, O G Open) - "Postpartum patients choosing lower-efficacy contraception valued advance provision of ulipristal acetate and reflected on ulipristal acetate as a user-controlled option, bolstering reproductive autonomy. Advance provision of ulipristal acetate can be a useful intervention to increase contraceptive access for postpartum patients before discharge."

Journal

Systematic review of interest-holder perceptions of pharmacist-prescribed ulipristal acetate emergency contraception. (PubMed, J Am Pharm Assoc (2003)) - "Pharmacist-prescribed UPA can enhance access to EC. Education, reimbursement, and support barriers must be addressed, in addition to legislation expansion, to enhance implementation."

Journal • Review

Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg (clinicaltrials.gov) - P4 | N=532 | Terminated | Sponsor: Kimberly Myer | N=1200 ➔ 532 | Unknown status ➔ Terminated; We weren't seeing as many pregnancies we initially thought.

Enrollment change • Trial termination

CCN013B: Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Premier Research | N=300 ➔ 0 | Suspended ➔ Withdrawn

Enrollment change • Trial withdrawal

Effects of female hormone withdrawal and ulipristal acetate on MED12 mutation positive and negative uterine leiomyomas using a xenograft model. (PubMed, Sci Rep) - "Gene ontology and pathway analyses of the differentially expressed genes of the xenograft tumors suggested that regression occurred by different mechanisms in the two subtypes. Our results also suggested, for the first time, that UPA caused SMC death by a mechanism other than progesterone receptor inhibition."

Journal • Preclinical • Oncology • Solid Tumor • Transplantation • Uterine Leiomyoma • MED12

Pricing of oral emergency contraception by German community pharmacies - a nationwide mystery caller investigation. (PubMed, Med Pharm Rep) - "The "morning after pill" (oral emergency contraception (EC)) with the active ingredients ulipristal acetate (UPA) and levonorgestrel (LNG) may only be dispensed by community pharmacies (CPs) in Germany...The price of UPA preparations is much higher than that of LNG preparations. High price levels and wide price ranges, especially for UPA preparations, could restrict access to oral EC."

Journal • Pricing

Efficacy and safety of emergency contraception interventions: a systematic review and Bayesian network meta-analysis. (PubMed, BMJ Sex Reprod Health) - "Although the efficacy of LNG-COX was confirmed by high-certainty evidence, large-scale validation trials are required before it can be recommended clinically. Owing to within-study bias and imprecision, large RCTs are strongly recommended to assess the efficacy of ECs for interventions without direct comparisons."

Journal • Retrospective data • Long-acting Reversible Contraceptives

Enhancing Access to Emergency Contraception: Results from a No-Cost Program in Utah. (PubMed, Contraception) - "This study supports removing cost and access barriers to emergency contraception, showing high demand for ulipristal acetate, and sustained use when offered without provider visits. This model demonstrates an innovative and feasible approach to deliver equitable access across diverse populations and regions via electronic portals and mail delivery systems."

Journal

Anti-progestin therapy targets hallmarks of breast cancer risk. (PubMed, Nature) - P2 | "Here, in the Breast Cancer-Anti-Progestin Prevention Study 1 (BC-APPS1; NCT02408770 ), we assessed whether progesterone receptor antagonism with ulipristal acetate for 12 weeks reduces surrogate markers of breast cancer risk in 24 premenopausal women...Culture of primary human breast epithelial cells in a stiff environment increased luminal progenitor activity, which was antagonized by anti-progestin therapy, strengthening this mechanistic link. This study offers a template for biologically informed early-phase therapeutic cancer prevention trials and demonstrates the potential for premenopausal breast cancer prevention with progesterone receptor antagonists through stromal remodelling and luminal progenitor suppression."

Journal • Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor

Safety of repeated use of emergency contraceptive pills in the same menstrual cycle: a systematic review. (PubMed, BMJ Sex Reprod Health) - "Evidence on the safety of repeated ECP use is limited and of very low certainty, but overall does not suggest safety concerns."

Journal • Review

EXPERIENCE IN THE MANAGEMENT OF UTERINE FIBROIDS WITH ULIPRISTAL ACETATE IN MEXICAN PATIENTS (FIGO 2025) - "This study describes the first experience in a Mexican-population. As shown, the efficacy of UPA in the first week of treatment of UF bleeding is confirmed with a high proportion of patients developing amenorrhoea. The average reduction in UF with a single cycle of treatment also appears significant."

Clinical • Gynecology • Hematological Disorders • Infertility • Sexual Disorders • Solid Tumor • Uterine Leiomyoma • Women's Health

Assessment of Hepatic Safety of Ulipristal Acetate in Korean Women with Uterine Fibroids: A Real-World Study Using Biochemical Markers. (PubMed, J Clin Med) - " UPA use in Korean women was associated with mild, subclinical elevations in liver enzymes and fatty liver index, but not with clinically significant hepatotoxicity. These findings support vigilant hepatic monitoring during UPA therapy, while contextualizing its risk as low in this population."

Journal • Real-world evidence • Gynecology • Hepatology • Liver Failure • Solid Tumor • Uterine Leiomyoma • Women's Health

Medical treatment of fibroids: FIGO best practice guidance. (PubMed, Int J Gynaecol Obstet) - "The previously approved therapy with ulipristal acetate had to undergo extensive restrictions because of safety concerns. These include combined oral contraceptives, oral progestins, the levonorgestrel-releasing intrauterine system (LNG-IUS), and tranexamic acid. Although not specifically approved for the treatment of fibroids, these agents can reduce the intensity of bleeding in cases of heavy menstrual bleeding and thereby improve symptoms and lead to an improved quality of life for the patients."

Journal • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health

Premium: Non-interventional Study to Evaluate Long Term Safety, Prescription Management Patterns of Esmya in a Long Term Setting (clinicaltrials.gov) - P=N/A | N=1527 | Completed | Sponsor: PregLem SA | Active, not recruiting ➔ Completed

Trial completion • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health

Effect of emergency contraception (ulipristal acetate) on growth, sexual differentiation, and reproduction in Oryzias latipes. (PubMed, Environ Toxicol Pharmacol) - "This study is the first to examine the effects of UPA on growth, gonadal sex differentiation, and reproduction in fish. Our results indicate that UPA has no effect on Japanese medaka and is thus an ecosystem-friendly emergency contraceptive."

Journal • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health

Ulipristal acetate for medical abortion: did we really need to create a 'monster'? (PubMed, Eur J Contracept Reprod Health Care) - No abstract available

Journal

Pharmacokinetic and Bioequivalence Evaluation of Ulipristal Acetate in Healthy Chinese Subjects in the Fasting and Postprandial Conditions. (PubMed, Clin Pharmacol Drug Dev) - "No data are available on the clinical importance of the food effect. Until such data becomes available, treating physicians should be aware of the increase in systemic exposure based on fasting versus postprandial conditions and plan dosage regimens accordingly."

Journal • PK/PD data • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health

Current treatment for symptomatic uterine fibroids: available evidence and therapeutic dilemmas. (PubMed, Lancet) - "This Review offers an evaluation of current treatments for symptomatic uterine fibroids, including uterine artery embolisation, MRI-guided high-intensity focused ultrasound, laparoscopic radiofrequency ablation, transcervical radiofrequency ablation, ulipristal acetate, and oral gonadotropin-releasing hormone antagonists with add-back therapy...Insight into these matters equips both patient and clinician with essential information to support the process of shared and fully informed decision making. Importantly, this Review also identifies knowledge gaps that contribute to the specification of the fibroid research agenda."

Journal • Review • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health

Drug development for adenomyosis based on pathophysiology. (PubMed, J Obstet Gynaecol Res) - "With a better understanding of adenomyosis pathophysiology, more druggable targets will be discovered."

Journal • Review • Endometriosis • Solid Tumor • Uterine Leiomyoma • Women's Health • DRD2

Frequency and patterns of emergency contraceptive demand among users of a UK-based free online sexual and reproductive health service: an observational study using routinely collected health data. (PubMed, BMJ Sex Reprod Health) - "A small group of people order EC repeatedly, sometimes within the same cycle, putting them at increased risk of pregnancy. A minority of people order doses of UPA of >150 mg in 30 days."

Journal • Observational data

In vitro apoptotic potential and ex vivo permeation analysis of ulipristal acetate loaded niosomes for management of uterine fibroids. (PubMed, J Microencapsul) - "UPA-NS induced higher ROS generation than free UPA. The niosomal formulation enhanced the cytotoxicity and ROS-generating potential of UPA against uterine fibroid cells."

Journal • Preclinical • Gynecology • Oncology • Solid Tumor • Uterine Leiomyoma • Women's Health

Transmasculine and gender nonbinary individuals' assigned female at birth experiences and preferences with emergency contraception.Transmasculine and gender nonbinary individuals' assigned female at birth experiences and preferences with emergency contraception. (ACOG 2025) - "Five (17%) used ulipristal acetate (UA)... Four hundred thirteen responded. The mean age was 34 (SD 8), and the majority identified as White (89%) and non-Hispanic (94%). Most were college educated (71%), and insured (91%)."

Clinical • Long-acting Reversible Contraceptives

Therapeutic Options for Unscheduled Bleeding on Hormonal Contraception. (PubMed, Obstet Gynecol Clin North Am) - "Small studies suggest that doxycycline, mifepristone, tranexamic acid, tamoxifen, ulipristal acetate, and clomiphene citrate may reduce bleeding in various contraceptive users. Mifepristone and tranexamic acid show promise for users of depot medroxyprogesterone acetate, implants, and intrauterine devices. While NSAIDs and combined oral contraceptives are commonly used, alternative therapies offer potential, though evidence remains limited."

Journal • Review • Long-acting Reversible Contraceptives